Detalles de la búsqueda
1.
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.
Breast Cancer Res Treat
; 203(1): 49-55, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37728693
2.
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery.
Jpn J Clin Oncol
; 54(5): 556-561, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38251759
3.
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
Breast Cancer Res
; 24(1): 67, 2022 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36217150
4.
Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer.
Breast Cancer Res Treat
; 196(2): 291-298, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36156756
5.
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
BMC Cancer
; 22(1): 31, 2022 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34980019
6.
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period.
Breast Cancer Res Treat
; 189(1): 225-236, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33966182
7.
Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy.
Radiology
; 299(1): 53-62, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33560188
8.
Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
Eur Radiol
; 30(6): 3363-3370, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32062698
9.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745582
10.
HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5).
Pathol Int
; 74(2): 99-101, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38197542
11.
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
Br J Cancer
; 118(12): 1571-1579, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29795308
12.
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Breast Cancer Res Treat
; 167(1): 81-87, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28895005
13.
[A Case of Long-Term Survival of Metastatic and Recurrent Duodenal Gastrointestinal Stromal Tumor Treated with Multimodality Managements].
Gan To Kagaku Ryoho
; 45(3): 527-529, 2018 Mar.
Artículo
en Japonés
| MEDLINE | ID: mdl-29650927
14.
[A Case of Long-Term Survival of the Pancreatic Tail Cancer with the Concomitant Small Liver Metastasis].
Gan To Kagaku Ryoho
; 45(2): 387-389, 2018 Feb.
Artículo
en Japonés
| MEDLINE | ID: mdl-29483456
15.
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Cancer Sci
; 108(5): 987-994, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28256066
16.
Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
Breast Cancer Res Treat
; 166(3): 911-917, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28852946
17.
Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
Breast Cancer Res Treat
; 162(1): 169-179, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28084583
18.
Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Breast Cancer Res Treat
; 161(3): 473-482, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28005247
19.
Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 162(3): 501-510, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28181129
20.
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Invest New Drugs
; 35(6): 791-799, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28660549